What Researchers Did
Researchers retrospectively analyzed the medical records of 92 hospitalized patients diagnosed with Clostridioides difficile infection to see if hyperbaric oxygen therapy affected their outcomes.
What They Found
The study found that patients who received hyperbaric oxygen therapy had a significantly lower recurrence rate of Clostridioides difficile infection (0%) compared to those who did not (22.4%). Additionally, the symptomatic period for patients receiving hyperbaric oxygen therapy was notably shorter, averaging 6.2 days compared to 13.6 days for the control group.
What This Means for Canadian Patients
For Canadian patients experiencing Clostridioides difficile infection, these findings suggest that hyperbaric oxygen therapy might help reduce how often the infection comes back and shorten the time they experience symptoms. This could potentially improve recovery and quality of life for individuals dealing with this challenging infection.
Canadian Relevance
This study was not conducted by Canadian authors or in Canada. Clostridioides difficile infection is not currently a Health Canada-recognized indication for hyperbaric oxygen therapy.
Study Limitations
This was a retrospective study where hyperbaric oxygen therapy was given for other medical conditions, not directly for the Clostridioides difficile infection itself, which limits the direct applicability of these findings.